1. Introduction {#s0005}
===============

Approximately, 10--15% of epithelial ovarian cancer (EOC) patients carry germline mutation in *BRCA1* or *BRCA2*. ([@bb0110]; [@bb0005]) The prevalence of *BRCA* mutation varies among different EOC subtypes. It is highest in high grade serous subtype which was reported up to 20--25%. ([@bb0055]; [@bb0060]) *BRCA* mutation was reported \<10% in endometrioid subtype and very low frequency in clear cell carcinoma and the other subtypes. ([@bb0010]) The knowledge about molecular studies showed that EOC is heterogeneous disease. It can be classified into two groups as type I and type II. Different in genomic variation characterizes by different in clinical presentation and prognosis. Type I is low grade and usually have indolent clinical course. ([@bb0095]) High grade is classified as type II, more aggressive and poor prognosis. Type II is considered to be more genomically instable than type I. Homologous recombination genes defect including *BRCA* genes are commonly detected in type II EOC. ([@bb0060]) Poly(ADP-ribose) polymerase (PARP) inhibitors have been reported to be a promising targeted therapy for *BRCA* deficient ovarian cancers. Phase 3 trials included recurrent platinum sensitive patients with high grade serous or high grade endometrioid EOC, primary peritoneal or fallopian tube carcinoma showed maintenance treatment with PARP inhibitors improved progression free survival. ([@bb0040]) The incidence of *BRCA* mutation might vary from one ethnicity and country to the others. The objective of this study was to identify the frequency of *BRCA* mutation in EOC Thai patients with high grade serous and high grade endometrioid subtype.

2. Materials and methods {#s0010}
========================

Patients diagnosed with EOC included fallopian tube cancer or peritoneal cancer who had *BRCA* testing from January 2015 to December 2017 were reviewed. EOC patients with high grade subtypes included high grade serous carcinoma and high grade endometrioid carcinoma were included. Patients with clear cell, mucinous carcinoma, carcinosarcoma or borderline tumor were excluded. Pathological review was performed by gynecologic pathologist. This study was approved by the Institutional Review Board, the Faculty of Medicine, Chulalongkorn University.

*BRCA1* and *BRCA2* mutations were tested using peripheral blood DNA samples or DNA extracted from formalin-fixed paraffin embedded block (FFPE) or a fresh tumor specimen then analyzed by next generation sequencing system (The Illumina MiSeq System; Illumina). The variant pathogenicity was evaluated based on the American College of Medical Genetics and Genomics (ACMG) standard and guidelines for the interpretation of sequence variants. ([@bb0090]) The variants conform to the guidelines of human genome variation society (HGVS) on mutation nomenclature and are referenced as sequence NM_007300.3 for *BRCA1* and NM_000059.3 for *BRCA2*. The pathogenic and likely pathogenic variants were confirmed using bi-directional Sanger sequencing. Patients who had *BRCA1* or *BRCA2* mutation in their tumor specimens were investigated by bi-directional Sanger sequencing using peripheral blood DNA to confirm germline or somatic *BRCA* mutation.

Student\'s *t*-test and Chi-square or Fisher\'s exact test were used to compare the continuous and categorical data, respectively. Statistical significance was defined as *p*-value \<.05.

3. Results {#s0015}
==========

A total of 87 patients were recruited into this study. Majority of the patients (88.5%) were EOC. Five patients (5.7%) were fallopian tube cancer, 4 patients (4.6%) peritoneal cancer, and 1 patient (1.1%) synchronous primary ovarian and endometrial cancer. The mean age was 55.6 ± 10.1 years (range 33--80), only 19 patients were younger than 50 years (21.8%). Fifty-three patients (60.9%) were menopausal and 29 patients (33.3%) were nulliparous. Sixteen patients (18.4%) had family history of breast cancer and/or ovarian cancers. Six patients (6.9%) had personal history of breast cancer before diagnosis of EOC. Most patients presented at the advanced stage: stage 3 (63.2%) and stage 4 (11.5%). One-fourth of the patients had early stage cancer: 12.6% had stage 1 and 12.6% had stage 2 cancer. Seven-four patients (85.1%) had high grade serous carcinoma and 13 (14.9%) had high grade endometrioid carcinoma.

Germline *BRCA* mutation was detected in 17 from 54 peripheral blood samples (12 *BRCA1* and 5 *BRCA2*) but only 2 pathogenic *BRCA1* mutations were detected from 33 tumor specimens. As for both patients, *BRCA1* mutations were confirmed and detected in the peripheral blood. Thus, the frequency of germline *BRCA* mutation was 19 in 87 patients (21.8%); 14 patients (16.1%) had *BRCA1* mutation, and 5 patients (5.7%) had *BRCA2* mutation. There was no somatic *BRCA* mutation in this study. Details of germline *BRCA* mutation in 19 patients were shown in [Table 1](#t0005){ref-type="table"}. All *BRCA* mutations were found in 19 patients with high grade serous carcinoma (25.7%). None with high grade endometrioid carcinoma had *BRCA* mutation. Clinicopathological characteristics were not different between patients with or without *BRCA* mutation, except significantly higher frequency of family history of breast and ovarian cancer in patients with *BRCA* mutation. ([Table 2](#t0010){ref-type="table"}) Based on age at diagnosis, 26.3% of patients who were younger than 50 years had BRCA mutation, compared with 32.4% of those older than 50 years (*p* = .78). *BRCA* mutation was found in 68.4% of patients with family history of cancer but only 4.4% in patients without family history (*p* \< .001). About 6 from 19 patients (31.6%) who had *BRCA* mutation had no family history of breast and ovarian cancers. Highest frequency of *BRCA* mutation was detected in fallopian tube cancer: 3 in 5 patients (60%) followed by peritoneal cancer: 2 in 4 patients (50%), and EOC: 14 in 77 patients (18.2%).Table 1Details of epithelial ovarian cancer patients with germline *BRCA* mutation.Table 1Age (years)GeneMutationVariant classificationCancerFamily history of cancerSynchronous cancersNucleotide changeProtein changeType64*BRCA1*c.981_982delATp.Cys328TerFrameshiftPathogenicOvarian cancer IIIBOvarian cancer (sister)--59*BRCA1*c.981_982delATp.Cys328TerFrameshiftPathogenicOvarian cancer IIICBreast cancer (sister)--72*BRCA1*c.3049G \> Tp.Glu1017TerNonsensePathogenicOvarian cancer IIIABreast cancer (2 sisters)--Endometrial cancer (mother)45*BRCA1*c.3049G \> Tp.Glu1017TerNonsensePathogenicOvarian cancer IVB----46*BRCA1*c.2059C \> Tp.Gln687TerNonsensePathogenicOvarian cancer IIICOvarian cancer (grandmother)--63*BRCA1*c.1889delAp.Asn630IlefsTer2FrameshiftPathogenicOvarian cancer IIICOvarian cancer (sister)--57*BRCA1*c.3770_3771delAGp.Glu1257GlyfsTer9FrameshiftPathogenicOvarian cancer IIICBreast cancer (aunt)--51*BRCA1*c.1426delCp.His476MetfsTer2FrameshiftPathogenicOvarian cancer IVBBreast cancer (Niece)--35*BRCA1*c.3020C \> Ap.Ser1007TerNonsensePathogenicOvarian cancer IIICBreast cancer (mother)--62*BRCA1*c.4327C \> Tp.Arg1443FrameshiftPathogenicPeritoneal cancer IIBBreast cancer (daughter)--Breast and ovarian cancer (sister)Endometrial cancer (sister)52*BRCA1*c.3748G \> Tp.Glu1250TerNonsensePathogenicPeritoneal cancer IIICBreast cancer (mother)--Ovarian cancer (sister)56*BRCA1*c.5072C \> Ap.Thr1691LysMissenseLikely pathogenicTubal cancer IIA----63*BRCA1*c.3181delAp.Ile1061TerFrameshiftPathogenicTubal cancer IVB----69*BRCA1*c.1155G \> Ap.Trp385TerNonsensePathogenicTubal cancer IC----60*BRCA2*c.3109C \> Tp.Gln1037TerNonsensePathogenicOvarian cancer IVBBreast cancer (2 sisters)Breast cancer56*BRCA2*c.7558C \> Tp.Arg2520TerNonsensePathogenicOvarian cancer IIIC----49*BRCA2*c.1367_1368delAGp.Lys457GlufsTer4FrameshiftPathogenicOvarian cancer IIICOvarian cancer (mother)Breast cancer49*BRCA2*c.4126G \> Tp.Gly1376TerNonsensePathogenicOvarian cancer IIICBreast cancer (sister)--Prostate cancer (uncle)Colon cancer (uncle)63*BRCA2*c.1405_1406delGAp.Asp469NonsensePathogenicOvarian cancer IIB--Breast cancerTable 2Clinicopathologic characteristics.Table 2*BRCA* positive (*N* = 19)*BRCA* negative (*N* = 68)*p*-ValueAge (years)56.2 ± 9.255.4 ± 10.40.49Nulliparous6 (31.6%)23 (33.8%)1.00Menopause12 (63.2%)41 (60.3%)1.00Family history of breast and ovarian cancer13 (68.4%)3 (4.4%)\<0.001Personal history of breast cancer3 (15.8%)3 (4.4%)0.12Type of cancer0.07 Epithelial ovarian cancer14 (73.7%)63 (92.6%) Fallopian tube cancer3 (15.8%)2 (2.9%) Peritoneal cancer2 (10.5%)2 (2.9%) Synchronous ovarian and endometrial cancer0 (0%)1 (1.5%)Histology0.06 High grade serous19 (100%)55 (80.9%) High grade endometrioid0 (0%)13 (19.1%)Stage0.35 I1 (5.3%)10 (14.7%) II3 (15.8%)8 (11.8%) III11 (57.9%)44 (64.7%) IV4 (21.1%)6 (8.8%)Platinum sensitive18 (94.7)55 (80.9)0.29

4. Discussion {#s0020}
=============

The worldwide incidence of *BRCA* mutations reported about 10--15%, and it was particularly high in high grade serous subtype, which was reported at about 20--30%. ([@bb0015]; [@bb0075]) Our study reported 25.7% incidence of germline *BRCA* mutation in high grade serous carcinoma which is the most common subtype worldwide; its incidence is around 70%. ([@bb0060]) In contrast, high grade serous carcinoma is much lower in Thailand; the incidence is only 22%. ([@bb0025]; [@bb0080]) The proportion of endometrioid and clear cell carcinoma are more frequent, up to 50%, whereas mucinous carcinoma was reported about 18% of them. ([@bb0080]) Our previous study reported the frequency of germline *BRCA* mutation about 11.4% in selected EOC patients with risk factors. However, higher frequency of *BRCA* mutation was reported in 18.2% of EOC patients with high grade serous subtype. ([@bb0025]) Thus, the frequency of *BRCA* mutation might be lower in unselected EOC patients in Thailand. The incidence of *BRCA* mutation might vary from one ethnicity and country to the others. Few studies reported the incidence of germline *BRCA* mutation in Asian countries, it was between 12 and 29%. ([@bb0030]; [@bb0020]; [@bb0045]; [@bb0100]; [@bb0105]). Highest incidence was reported in the Chinese (29%) and Koreans (26%). The incidence of high grade serous subtype in these two countries are similar to the western countries which was 73% and 63%, respectively. Most patients with *BRCA* mutation in those studies had high grade serous subtype. Incidence of *BRCA* mutation in high grade serous subtype were reported as high as 30--40%. ([@bb0030]; [@bb0105]) This incidence is slightly higher than our study, which showed about 25.7%. Previous systematic review showed lower probability of having germline *BRCA* mutation in endometrioid subtype, which was reported about 7.7% (95%CI 4.8--10.6). ([@bb0010]) However, no *BRCA* mutation was found in patients with high grade endometrioid carcinoma in our study.

The incidence of *BRCA* mutation in patients without family history of breast and/or ovarian cancers was reported about 10%. ([@bb0070]) In contrast, 60--70% of patients with family history of cancers had *BRCA* mutation. ([@bb0105]; [@bb0085]) This finding is in concordance with finding that showed 4.4% and 68.4% of patients without and with family history of cancers who had *BRCA* mutation. If patients were selected based on family history of cancers, at least 30% of patients may be missed.

Age of onset below 50 years is one important factor associated with *BRCA* status. Almost 50% of Israeli EOC patients younger than 50 years carried *BRCA* mutation. ([@bb0050]) Jewish is a specific ethnicity associated with increased rate of *BRCA* mutation. As this result, this number is much higher than the other studies which reported 22--33% of patients younger than 50 years carried *BRCA* mutation. ([@bb0005]; [@bb0105]; [@bb0035]) This number was concordance to our finding which reported about 26.3%.

In general, *BRCA* testing is recommended to offer in all patients with EOC including fallopian tube and peritoneal cancer. Fallopian tube is believed to be the original site for development of pelvic serous cancers. There is evidence that fallopian tube and peritoneal cancer also relate to *BRCA* mutations. The prevalence of *BRCA* mutation in fallopian tube and peritoneal cancer was reported to be higher than EOC. Previous studies showed 20--40% of patients with these cancers had *BRCA* mutation. ([@bb0035]; [@bb0065]) Although there were limited number of patients, *BRCA* mutation tended to be higher in fallopian tube and peritoneal cancers, 60% and 50%, respectively.

The limitation in this study was *BRCA* testing did not test in both tumor tissue and peripheral blood in all patients. Therefore, the exact incidence of somatic *BRCA* mutation can not be identified. However, 2 in 33 patients who found *BRCA* mutation in tumor tissue also had *BRCA* mutation in peripheral blood. Germline *BRCA* mutation was diagnosed and there was no somatic *BRCA* mutation in this small subset of patients. Moreover, this study was conducted at only one tertiary center; this may not represent the incidence of *BRCA* mutation in Thai population.

The incidence of germline mutation in high grade subtype in this study was 21.8%. However, all *BRCA* mutation was found in high grade serous subtype, none in high grade endometrioid subtype. Although, various societies such as American College of Obstetricians and Gynecologists (ACOG), Society of Gynecologic Oncologists (SGO), and National Comprehensive Cancer Network (NCCN) have recommended universal genetic counseling and testing for all EOC patients, high cost, unavailability of genetic testing, and limited number of geneticists, may be barriers in limited resource countries. From our previous survey, only 25% of patients knew that ovarian cancer may be inherited and only 16% of them knew that there is a test to evaluate. Interestingly, high rate of acceptance for genetic testing was reported up to 75% of them. ([@bb0025]) It is one major challenge to improve knowledge and increase patient awareness. Although, increasing centers in both public and private sectors provide genetic testing service, limited number of geneticists and high cost are still important barriers. The expense for genetic testing is not covered by the Universal Coverage Scheme yet, only government or state enterprise officers can get partial reimbursement. Selected patients especially high grade serous subtype and/or patients who had strong family history of breast and/or ovarian cancers should be considered initially in Thailand.
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